Should You Buy or Sell AbbVie Stock at $230?

AbbVie (ABBV) is currently trading around $230, after successfully offsetting the decline in Humira revenues with new products like Skyrizi and Rinvoq. But the question remains: does the current price present a buying opportunity or a selling signal?

Analyst Rationale

Analysts note that AbbVie has restructured its drug portfolio faster than expected, mitigating the impact of Humira's patent expiration. However, the stock trades at a relatively high price-to-earnings multiple compared to peers like Johnson & Johnson (JNJ) and Merck (MRK).

Context

AbbVie faces competitive pressures in the autoimmune drug market, where its products compete with those from Bristol-Myers Squibb (BMY) and Gilead Sciences (GILD). Future revenue growth depends on successful clinical trials and expansion into new markets.

Conclusion

There is no clear buy or sell recommendation at this price. Investors are encouraged to assess their risk tolerance and AbbVie's long-term growth prospects amid intense competition.